Physiomics PLC
LSE:PYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Infotmic Co Ltd
SZSE:000670
|
CN |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (0), the stock would be worth GBX-0 (101% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.5 | GBX0.48 |
0%
|
| Industry Average | 0 | GBX-0 |
-101%
|
| Country Average | 0 | GBX-0 |
-101%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Physiomics PLC
LSE:PYC
|
2.2m GBP | -3.5 | -3 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 360.7 | 4 278.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
197.4B USD | 27.3 | 29.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
137.5B USD | 28.1 | 38.1 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
35.1B CHF | 26.7 | -125 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
294B CNY | 16 | 15.4 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.5B USD | 23.2 | 26.8 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.9B USD | 41.5 | 51.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.8B USD | 18.2 | 22 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | 25.5 | 31 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0.1 |
| Max | 1 015 |
Other Multiples
Physiomics PLC
Glance View
Physiomics Plc engages in the provision of outsourced systems and computational biology services to pharmaceutical companies. The company is headquartered in Oxford, Oxfordshire and currently employs 7 full-time employees. The company went IPO on 2004-12-20. The firm offer Virtual Tumour technology and other tools to predict the effects of cancer treatments. The Company’s Virtual Tumour software platform is used to simulate the effects of anti-cancer agents on pre-clinical and human tumors. The company is used by companies ranging from startup biotech to global large-cap pharmaceuticals. The firm provides a range of Pharmacokinetic/Pharmacodynamics (PK/PD) services, usually in support of smaller companies where this function is outsourced. The Company’s services include oncology specialists, mechanistic modelling, PK/PD, quantitative systems pharmacology and mathematical modelling.
